Clinical Aspects Of Hypertensive Patients With COVID-19 Hospitalized In A Campaign Hospital In Northeast Brazil

Abstract

Since the first cases of coronavirus disease 2019 in December 2019, in the city of Wuhan, China, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was responsible for the death of more than 3.6 million people, as of June 2021. It has a lethality rate of around 2.15% worldwide, with 171 million people infected, according to data from the World Health Organization. 1,2 In view of the absence of proven effective therapy for the disease, numerous studies have been developed seeking to identify the determining factors for the development of more severe forms of COVID-19, in order to direct efforts to avoid the worst outcomes in patients with possible profiles of development of severe conditions. 3 Several comorbidities have been associated with the most complicated forms of COVID-19, 4 including systemic arterial hypertension (SAH), a disease that has a prevalence of around 26% in the world's adult population 5 and a prevalence of 24.5% in Brazilian capital cities. 6 Furthermore, several studies have pointed to SAH as the most frequent comorbidity in patients diagnosed with COVID-19 worldwide.